Limerick BioPharma

About Limerick BioPharma

Limerick BioPharma is a privately held biopharmaceutical company headquartered in South San Francisco, California. The company was established in 2005 by Wendye Robbins, M.D., who also serves as its CEO. Dr. Robbins brought prior entrepreneurial experience to the venture, having been the scientific founder and president of NeurogesX, a company focused on pain therapies.

The firm's core focus is the development of compounds that can be used adjunctively with other marketed and investigational drugs to improve their side effect profiles and overall clinical outcomes. This is achieved through a proprietary platform centered on 'Cellular Transporter Pump Activators'. These activators are designed to trigger cellular pumps in specific tissues, such as the kidney or liver, causing them to redistribute drugs away from these organs where they might otherwise cause toxic or adverse effects. This approach essentially provides a 'chaperone' drug that mitigates the toxicity threats limiting the efficacy or viability of other therapeutic agents.

Limerick BioPharma's business model is geared towards partnering with pharmaceutical companies at an early stage. The strategy involves collaborating with firms that have existing drugs with known side effects or experimental therapies that have encountered toxicity hurdles in development, including those that may have failed in late-stage trials. The company's pipeline has shown potential applications in several areas, including metabolic disease, immunosuppression, and mitigating the side effects of opiates. An unexpected discovery also indicated that some activators could restore islet cell function and resolve issues with blood sugar and lipids, opening a potential standalone therapeutic path.

To finance its operations, Limerick BioPharma has successfully completed several funding rounds, raising a total of $47.1 million. Notable rounds include a $5.5 million Series A in 2006 and a $15 million Series C in 2009, which was led by OVP Venture Partners with participation from existing investors like ARCH Venture Partners and Sevin Rosen Funds. This funding was intended to advance the company's lead programs through Phase I safety studies and into Phase II proof-of-concept trials.